Atara Q3 revenue falls to $1.22M as net loss narrows

Nine-month costs and operating expenses fell approximately 83% year over year; commercialization revenue was $2.370 million.

Available on EDGAR 11/10/2026 - 04:11 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. (ATRA) reported third-quarter 2026 commercialization revenue of $1.224 million versus $3.453 million in 2025, and a net loss of $2.229 million versus $4.303 million. For the nine months ended September 30, 2026, revenue was $2.370 million versus $119.177 million in 2025; net loss was $11.208 million versus net income of $36.094 million. Nine-month costs and operating expenses were $13.429 million versus $80.752 million, an approximately 83% year-over-year reduction. Cash and cash equivalents were $4.055 million and short-term investments were $5.862 million as of September 30, 2026.

The FDA accepted the BLA resubmission for tabelecleucel (tab-cel) for proposed monotherapy in adult and pediatric patients age two and older with EBV-positive PTLD after at least one prior therapy; the PDUFA target action date is March 31, 2027. If approved, Atara would be eligible for a $31 million milestone payment under its agreement with Pierre Fabre Laboratories, plus tiered royalties on net sales and commercial-sales milestones. Pierre Fabre Pharmaceuticals holds and controls the BLA and its FDA interaction strategy; Atara says its ability to influence the review is limited.

1 point · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

How the balance works

Positive

• Moderate pointNine-month costs and operating expenses fell approximately 83% year over year.

Negative

• Major pointNine-month commercialization revenue: $2.370 million, versus $119.177 million in 2025.
• Moderate pointNine-month net loss: $11.208 million, versus $36.094 million net income in 2025.

Filing Explained

The balance sheet lists 10,188 thousand common shares issued and outstanding at September 30, 2026, versus 7,324 thousand at December 31, 2025; for a holder whose share count stayed unchanged, that larger total represents a smaller ownership fraction.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Third-quarter commercialization revenue: $1.224 million Third-quarter net loss: $2.229 million Nine-month commercialization revenue: $2.370 million +5 more

8 metrics

Third-quarter commercialization revenue $1.224 million Three months ended September 30, 2026; $3.453 million in 2025

Third-quarter net loss $2.229 million Three months ended September 30, 2026; $4.303 million in 2025

Nine-month commercialization revenue $2.370 million Nine months ended September 30, 2026; $119.177 million in 2025

Nine-month net loss $11.208 million Nine months ended September 30, 2026; net income of $36.094 million in 2025

Nine-month costs and operating expenses $13.429 million Nine months ended September 30, 2026; $80.752 million in 2025, an approximately 83% year-over-year reduction

Cash and cash equivalents $4.055 million As of September 30, 2026

Short-term investments $5.862 million As of September 30, 2026

Potential approval milestone $31 million Atara would be eligible for payment if tabelecleucel is approved by the FDA

Key Terms

PDUFA target action date, Biologics License Application, EBV+ PTLD, tiered royalties

4 terms

PDUFA target action date regulatory

"Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date"

The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.

Biologics License Application regulatory

"accepted the Biologics License Application (BLA) resubmission"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

EBV+ PTLD medical

"Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)"

A condition in which the Epstein‑Barr virus (EBV) triggers uncontrolled growth of a transplant patient’s immune cells, called post‑transplant lymphoproliferative disorder (PTLD). It behaves like invasive weeds taking over a garden when the body’s immune “fence” is weakened by anti‑rejection drugs, and can be life‑threatening without rapid diagnosis and treatment. Investors watch EBV+ PTLD because it creates a focused, urgent market for diagnostics, therapies and hospital care, so clinical trial results, approvals or new treatments can materially affect companies working in transplant, oncology and infectious disease.

tiered royalties financial

"significant double-digit tiered royalties as a percentage of net sales"

Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.

Earnings Snapshot

Commercialization revenue, three months ended September 30, 2026: $1.224 million

Third quarter and nine months ended September 30, 2026

Commercialization revenue, three months ended September 30, 2026 $1.224 million Compared with $3.453 million in the three months ended September 30, 2025

Commercialization revenue, nine months ended September 30, 2026 $2.370 million Compared with $119.177 million in the nine months ended September 30, 2025

Total costs and operating expenses, nine months ended September 30, 2026 $13.429 million Compared with $80.752 million in the nine months ended September 30, 2025

Net income (loss), nine months ended September 30, 2026 $11.208 million loss Compared with $36.094 million net income in the nine months ended September 30, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atara Biotherapeutics (ATRA) report for the third quarter of 2026?

ATRA reported commercialization revenue of $1.224 million and a net loss of $2.229 million for the three months ended September 30, 2026. In the comparable 2025 quarter, commercialization revenue was $3.453 million and net loss was $4.303 million.

When is the FDA's target action date for Atara's tab-cel BLA?

The PDUFA target action date for the Class 2 resubmission is March 31, 2027. The proposed use is monotherapy for adult and pediatric patients two years of age and older with Epstein-Barr virus positive PTLD who have received at least one prior therapy.

What could Atara receive if tab-cel is approved?

If the FDA approves tabelecleucel, Atara would be eligible for a $31 million milestone payment under its commercialization agreement with Pierre Fabre Laboratories. The agreement also provides for significant double-digit tiered royalties as a percentage of net sales and milestones related to commercial sales of EBVALLO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001604464false00016044642026-11-102026-11-10

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 10, 2026

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

​	​	​	​	​
Delaware	​ ​ ​	001-36548	​ ​ ​	46-0920988
(State or Other Jurisdiction of Incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)
​	​	​	​	​
1280 Rancho Conejo Blvd	​	​	​	​
Thousand Oaks, California	​	​	​	91320
(Address of Principal Executive Offices)	​	​	​	(Zip Code)

​

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

​

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	​	ATRA	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02 Results of Operations and Financial Condition.

​

On November 10, 2026, Atara Biotherapeutics, Inc. (the “Company”) announced certain financial results for the quarter ended September 30, 2026. A copy of the Company’s press release, titled “Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress” is furnished as Exhibit 99.1 hereto.

The information set forth in this Item 2.02 and in the press release included as Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

​

Item 9.01 Financial Statements and Exhibits.

(d)      Exhibits.

​

Exhibit No.	​ ​ ​	Description
​	​	​
99.1	​	Press Release, dated November 10, 2026
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

No	​	​	​
​	​	​	ATARA BIOTHERAPEUTICS, INC.
​	​	​	​
Date:	November 10, 2026	By:	/s/ AnhCo Thieu Nguyen, Ph.D.
​	​	​	AnhCo Thieu Nguyen, Ph.D. President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)

​

Exhibit 99.1

Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress

Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027

Approval of BLA would unlock a $31 Million milestone payment from Pierre Fabre Laboratories

Nine-month year over year reduction in costs and operating expenses of approximately 83%

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2026 and business updates.

“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “We continue to believe in tab-cel’s significant commercial potential in the U.S. In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”

Tabelecleucel (tab-cel^® or EBVALLO™) for Post-Transplant Lymphoproliferative Disease (PTLD)

As previously communicated, the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for tabelecleucel, with a proposed indication as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.

The BLA has a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027.

If tabelecleucel is approved by the FDA, Atara would be eligible to receive a $31 million milestone payment pursuant to Atara’s commercialization agreement with Pierre Fabre Laboratories. Atara would also be eligible to receive significant double-digit tiered royalties as a percentage of net sales, as well as milestones related to commercial sales of EBVALLO.

Third Quarter 2026 Financial Results:

● Cash, cash equivalents and short-term investments as of September 30, 2026, totaled $9.9 million, as compared to $9.9 million as of June 30, 2026.

● Net cash used in operating activities was $0.9 million for the third quarter 2026, as compared to $9.8 million in the same period in 2025.

● Total revenues were $1.2 million for the third quarter 2026, as compared to $3.5 million for the same period in 2025. Total revenues decreased by $2.3 million year-over-year, primarily due to the one-time sale of clinical inventory in the prior year.

● Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $0.5 million for the third quarter 2026, as compared to $1.3 million for the same period in 2025.

● Research and development expenses were $1.1 million for the third quarter 2026, as compared to $2.9 million for the same period in 2025.

● Research and development expenses include $0.1 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to $0.3 million for the same period in 2025.

● General and administrative expenses were $2.8 million for the third quarter 2026, as compared to $4.0 million for the same period in 2025.

● General and administrative expenses include $0.4 million of non-cash stock-based compensation expenses for the third quarter 2026, as compared to $0.9 million for the same period in 2025.

● Atara reported a net loss of $2.2 million, or ($0.15) basic and diluted loss per share, for the third quarter 2026, as compared to net loss of $4.3 million, or ($0.32) basic and diluted loss per share, for the same period in 2025.

​

2026 Outlook and Cash Runway:

● Operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026.

● Atara expects its cash, cash equivalents, and short-term investments as of September 30, 2026, combined with operating efficiencies achieved in 2025 and the first half of 2026, will be sufficient to fund planned operations into mid-2027.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the FDA’s review of the resubmitted tab-cel BLA and the PDUFA target action date, the potential characteristics and benefits of tab-cel, and the results of, and prospects for bringing tab-cel to U.S. patients with EBV+ PTLD, the global partnership with Pierre Fabre

Medicament involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Medicament, including the receipt, timing and amount of any payments to be received by Atara thereunder; and (2) Atara’s cash runway, receipt of potential milestone payments, and estimated reduction in operating expenses, including Atara’s ability to fund its planned operations into mid-2027. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel, including the risk that the resubmitted tab-cel BLA may not address the deficiencies identified in the Complete Response Letter received on January 9, 2026 or other issues that may be raised by the FDA on review; the fact that PFP, and not Atara, holds the tab-cel BLA and controls the content and strategy of the BLA and related FDA interactions, and Atara's ability to influence the review process is limited; Atara’s ability to continue as a going concern and access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Atara’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

​

​

Atara Biotherapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except per share amounts)

​

​	​	​	​	​	​	​
​	​	September 30,		​	December 31,
​	​ ​ ​	2026		​ ​ ​	2025
Assets	​	​	​	​	​	​
Current assets:	​	​	​	​	​	​
Cash and cash equivalents	​	$	4,055	​	$	8,482
Short-term investments	​	​	5,862	​	​	—
Accounts receivable	​	​	691	​	​	1,253
Other current assets	​	​	705	​	​	2,477
Total current assets	​	​	11,313	​	​	12,212
Property and equipment, net	​	​	38	​	​	73
Operating lease assets	​	​	6,494	​	​	7,064
Other assets	​	​	762	​	​	886
Total assets	​	$	18,607	​	$	20,235
​	​	​	​	​	​	​
Liabilities and stockholders’ equity (deficit)	​	​	​	​	​	​
Current liabilities:	​	​	​	​	​	​
Accounts payable	​	$	762	​	$	127
Accrued compensation	​	​	471	​	​	1,271
Accrued research and development expenses	​	​	24	​	​	82
Deferred revenue	​	​	513	​	​	716
Liability related to the sale of future revenues – current portion	​	​	1,105	​	​	9,750
Other current liabilities	​	​	3,693	​	​	2,976
Total current liabilities	​	​	6,568	​	​	14,922
Operating lease liabilities – long-term	​	​	8,482	​	​	9,347
Liability related to the sale of future revenues – long-term	​	​	39,560	​	​	32,673
Other long-term liabilities	​	​	1,899	​	​	1,795
Total liabilities	​	​	56,509	​	​	58,737
​	​	​	​	​	​	​
Commitments and contingencies	​	​	​	​	​	​
​	​	​	​	​	​	​
Stockholders’ equity (deficit):	​	​	​	​	​	​
Common stock—$0.0001 par value, 500,000 shares authorized as of September 30, 2026 and December 31, 2025; 10,188 and 7,324 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	​	​	1	​	​	1
Additional paid-in capital	​	​	1,995,171	​	​	1,983,361
Accumulated other comprehensive income (loss)	​	​	(1)	​	​	1
Accumulated deficit	​	​	(2,033,073)	​	​	(2,021,865)
Total stockholders’ equity (deficit)	​	​	(37,902)	​	​	(38,502)
Total liabilities and stockholders’ equity (deficit)	​	$	18,607	​	$	20,235

​

​

​

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except per share amounts)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

​ ​ ​

2026

​ ​ ​

2025

​ ​ ​

2026

​ ​ ​

2025

Commercialization revenue

​

$

1,224

​

$

3,453

​

$

2,370

​

$

119,177

Costs and operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Cost of commercialization revenue

​

​

265

​

​

115

​

​

580

​

​

21,108

Research and development expenses

​

​

1,099

​

​

2,925

​

​

2,608

​

​

37,668

General and administrative expenses

​

​

2,830

​

​

3,987

​

​

10,241

​

​

21,976

Total costs and operating expenses

​

​

4,194

​

​

7,027

​

​

13,429

​

​

80,752

Income (loss) from operations

​

​

(2,970)

​

​

(3,574)

​

​

(11,059)

​

​

38,425

Other income (expense), net:

​

​

​

​

​

​

​

​

​

​

​

​

Interest income

​

​

68

​

​

204

​

​

199

​

​

583

Interest income (expense) on sale of future revenues

​

​

682

​

​

(906)

​

​

(333)

​

​

(2,745)

Other income (expense), net

​

​

(9)

​

​

1

​

​

(14)

​

​

(138)

Total other income (expense), net

​

​

741

​

​

(701)

​

​

(148)

​

​

(2,300)

Income (loss) before provision for (benefit from) income taxes

​

​

(2,229)

​

​

(4,275)

​

​

(11,207)

​

​

36,125

Provision for (benefit from) income taxes

​

​

—

​

​

28

​

​

1

​

​

31

Net income (loss)

​

$

(2,229)

​

$

(4,303)

​

$

(11,208)

​

$

36,094

Other comprehensive gain (loss):

​

​

​

​

​

​

​

​

​

​

​

​

Unrealized gain (loss) on available-for-sale securities

​

​

1

​

​

2

​

​

(2)

​

​

(6)

Comprehensive income (loss)

​

$

(2,228)

​

$

(4,301)

​

$

(11,210)

​

$

36,088

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic (loss) earnings per common share

​

$

(0.15)

​

$

(0.32)

​

$

(0.76)

​

$

2.96

Diluted (loss) earnings per common share

​

$

(0.15)

​

$

(0.32)

​

$

(0.76)

​

$

2.93

​

​

​

​

​

​

​

​

​

​

​

​

​

Basic and diluted weighted-average shares outstanding

​

​

15,326

​

​

13,564

​

​

14,818

​

​

12,185

Diluted weighted-average shares outstanding

​

​

15,326

​

​

13,564

​

​

14,818

​

​

12,319

​

​

Investor and Media Relations Amber Daugherty Sr. Director, Strategy and Operations adaugherty@atarabio.com

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 200.5 KB

Other Documents

• EX-101 EX-101.SCH 3.4 KB
• EX-101 EX-101.DEF 2.8 KB
• EX-101 EX-101.LAB 16.2 KB
• EX-101 EX-101.PRE 10.7 KB